Skip to main content
The Markets by Proactive
Go to Proactive Australia

Archive

The Vaccine Group delivers 'strong' preclinical results from next-generation Covid jab

The Vaccine Group delivers 'strong' preclinical results from next-generation Covid jab

Frontier IP Group PLC (AIM:FIPP) (Frontier IP Group PLC (AIM:FIPP)) investee company The Vaccines Group CEO Jeremy Salt joins Proactive London's Katie Pilbeam after delivering encouraging pre-clinical results for a next-generation Covid inoculation.

Data from The Vaccines Group revealed its herpesvirus-based jab stimulated a strong T cell response when used on pigs.

Frontier owns 17% of The Vaccine Group.